Does carvedilol therapy reduce QT dispersion in patients with heart failure?

Basit Öğe Kaydı
dc.contributor.authorTatli, Ersan
dc.contributor.authorAktoz, Meryern
dc.contributor.authorGul, Cetin
dc.contributor.authorBuyuklu, Mutlu
dc.contributor.authorKurum, Turhan
dc.date.accessioned2024-06-12T10:55:51Z
dc.date.available2024-06-12T10:55:51Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: Carvedilol therapy increases left ventricular ejection fraction, and reduces mortality and morbidity rates. However, there are very limited data relating to the effect of carvedilol on QT dispersion (QTd). In this study, we investigated the effect of carvedilol therapy on QTd in patients with heart failure. Material and methods: Fifty-six patients with heart failure and a left ventricular ejection fraction less than 40% were prospectively included in the study. Clinical examination, determinations of plasma levels of tumour necrosis factor-alpha (TNF-alpha), interleukin 2 (IL-2) and IL-6, electrocardiography and radionuclide study were performed at baseline and repeated at the end of the 4(th) month of carvedilol therapy. From standard 12-lead electrocardiograms the maximum and minimum QT intervals, corrected QT intervals and corrected QTd values were calculated at baseline, and after the 4(th) month of carvedilol therapy. Results: At the end of the 4(th) month, IL-6 (from 9.8 +/- 6.4 to 5.4 +/- 0.7 pg/ml) and TNF-a (from 10.9 +/- 4.6 to 6.0 +/- 4.9 pg/ml) levels, QTd, corrected QTd, resting heart rate, and Systolic blood pressure were significantly decreased, and left ventricular ejection fraction and NYHA functional class were improved by carvedilol therapy (QTd from 66 +/- 22 to 28 +/- 13 ms, P<0.001, corrected QTd from 72 +/- 23 to 30 +/- 14 ms, P<0.001). However, maximum corrected QT and maximum QT values did not change significantly, while minimum QT and minimum corrected QT values significantly increased. Conclusions: Carvedilol therapy for 4 months resulted in a significant reduction in QTd.en_US
dc.identifier.endpage408en_US
dc.identifier.issn1734-1922
dc.identifier.issn1896-9151
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-60249097877en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage404en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19579
dc.identifier.volume4en_US
dc.identifier.wosWOS:000264301900010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTermedia Publishing House Ltden_US
dc.relation.ispartofArchives Of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCarvedilolen_US
dc.subjectHeart Failureen_US
dc.subjectQT Dispersionen_US
dc.subjectCytokinesen_US
dc.subjectLeft-Ventricular Functionen_US
dc.subjectBeta-Blockersen_US
dc.subjectDilated Cardiomyopathyen_US
dc.subjectClinical-Trialsen_US
dc.subjectDouble-Blinden_US
dc.subjectArrhythmiasen_US
dc.subjectCapricornen_US
dc.subjectEventsen_US
dc.subjectDeathen_US
dc.titleDoes carvedilol therapy reduce QT dispersion in patients with heart failure?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu